Line 7: | Line 7: | ||
==OVERVIEW== | ==OVERVIEW== | ||
− | |||
<p> Synthetic biology isn’t easy to explain to non-scientists. But explaining CRISPR-Cas9 is way harder. Not only because those matters are complex, but also because we still don’t know precisely the consequences of such technologies. If CRISPR-Cas 9 is undoubtedly a revolution, the seism affects other fields, interconnected with science (ethics or law as an example). </p> | <p> Synthetic biology isn’t easy to explain to non-scientists. But explaining CRISPR-Cas9 is way harder. Not only because those matters are complex, but also because we still don’t know precisely the consequences of such technologies. If CRISPR-Cas 9 is undoubtedly a revolution, the seism affects other fields, interconnected with science (ethics or law as an example). </p> | ||
Line 21: | Line 20: | ||
− | + | == I/ Reflexivity == | |
<p> When we chose our project we had different options. We chose to take a fundamental project, riskier but more original. </p> | <p> When we chose our project we had different options. We chose to take a fundamental project, riskier but more original. </p> | ||
Line 31: | Line 30: | ||
<p> With this reflexion came the main question the RRI test asked us : how RRI could apply to fundamental research, such as our project on CRISPR-Cas9 ? The societal goal doesn’t seem to exist. However, building a responsible research is in itself a societal goal : having a more responsible science is undoubtedly a benefit for the society. The stakeholders of a fundamental project are the ones whose voices are interesting and necessary on science. In other words, the stakeholders are less identified. On our focus on CRISPR-Cas9 we felt necessary to gather stakeholders and tried to draw with them the future of a responsible use on this technology. </p> | <p> With this reflexion came the main question the RRI test asked us : how RRI could apply to fundamental research, such as our project on CRISPR-Cas9 ? The societal goal doesn’t seem to exist. However, building a responsible research is in itself a societal goal : having a more responsible science is undoubtedly a benefit for the society. The stakeholders of a fundamental project are the ones whose voices are interesting and necessary on science. In other words, the stakeholders are less identified. On our focus on CRISPR-Cas9 we felt necessary to gather stakeholders and tried to draw with them the future of a responsible use on this technology. </p> | ||
− | + | == II/ Anticipation == | |
<p> The more we knew about CRISPR-Cas9, the more we realised we didn’t know much on this technology and its impacts. The difficult anticipation in the scientific field transferred our questions on the human practice, and we try to learn from stakeholders what the burning issues can be on CRISPR-Cas9, and tried to get people know more about it. </p> | <p> The more we knew about CRISPR-Cas9, the more we realised we didn’t know much on this technology and its impacts. The difficult anticipation in the scientific field transferred our questions on the human practice, and we try to learn from stakeholders what the burning issues can be on CRISPR-Cas9, and tried to get people know more about it. </p> | ||
− | + | == III/ Inclusiveness/Deliberation== | |
<p> As our project was in the field of synthetic biology, we had a strong concern about inclusiveness. We met a lot of stakeholders and public. In our case of fundamental research we defined the stakeholders as scientists using CRISPR-Cas9 and counselors in industrial property.</p> | <p> As our project was in the field of synthetic biology, we had a strong concern about inclusiveness. We met a lot of stakeholders and public. In our case of fundamental research we defined the stakeholders as scientists using CRISPR-Cas9 and counselors in industrial property.</p> | ||
− | + | ===VULGARISATION : A KEY CONCERN=== | |
<p> As we believe scientific vulgarisation is a key concern in synthetic biology and especially for CRISPR-Cas9, we lead several actions of vulgarisation. </p> | <p> As we believe scientific vulgarisation is a key concern in synthetic biology and especially for CRISPR-Cas9, we lead several actions of vulgarisation. </p> | ||
Line 47: | Line 46: | ||
<p> What did we learn of this experiments ? Most of the people we met trust scientist to be responsible in their use, and doesn’t feel legitimate to bring a critic on a subject they don’t master. </p> | <p> What did we learn of this experiments ? Most of the people we met trust scientist to be responsible in their use, and doesn’t feel legitimate to bring a critic on a subject they don’t master. </p> | ||
− | + | ===MEETING STAKEHOLDERS=== | |
− | + | ===CONFERENCE : THE SOCIETAL ISSUES OF CRISPR-CAS9=== | |
<p> Because we had a strong concern both on vulgarisation and meeting stakeholders, we hold a conference in our university, in front of students, with two researchers, Jean Denis Faure, a researcher and teacher using CRISPR-Cas9 on plants, and Pierre Walrafen a scientific with a cellular biochemistry and patent engineer. </p> | <p> Because we had a strong concern both on vulgarisation and meeting stakeholders, we hold a conference in our university, in front of students, with two researchers, Jean Denis Faure, a researcher and teacher using CRISPR-Cas9 on plants, and Pierre Walrafen a scientific with a cellular biochemistry and patent engineer. </p> | ||
Line 57: | Line 56: | ||
<p> About the legal framework, our speakers made a comparison between the European legal framework, the process based evaluation, and the product based evaluation, and how the patentability was in Europe restrained by a principle of public order. </p> | <p> About the legal framework, our speakers made a comparison between the European legal framework, the process based evaluation, and the product based evaluation, and how the patentability was in Europe restrained by a principle of public order. </p> | ||
− | + | ===iGEM MEET-UPS=== | |
<p> We attend to two iGEM meet-ups, an European one, and an other, gathering the Parisian teams. We were part of the organisation of the Parisian meet-up. </p> | <p> We attend to two iGEM meet-ups, an European one, and an other, gathering the Parisian teams. We were part of the organisation of the Parisian meet-up. </p> | ||
Line 63: | Line 62: | ||
<p> This meet-ups helps us in two ways. First it was a great opportunity to have a feed-back from our peers. Then, we met there other teams working with CRISPR-Cas9, and lead collaborations with them. </p> | <p> This meet-ups helps us in two ways. First it was a great opportunity to have a feed-back from our peers. Then, we met there other teams working with CRISPR-Cas9, and lead collaborations with them. </p> | ||
− | + | == IV/ Responsiveness== | |
<p> What did we learn ? </p> | <p> What did we learn ? </p> | ||
Line 89: | Line 88: | ||
− | + | <br><br><br><br><br><br><br><br> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
Revision as of 09:27, 14 September 2016